Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis ; volume:37 ; number:9 ; day:4 ; month:8 ; year:2020 ; pages:4033-4042 ; date:9.2020
Advances in therapy ; 37, Heft 9 (4.8.2020), 4033-4042, 9.2020
- Urheber
-
Lampertico, Pietro
Mauss, Stefan
Persico, Marcello
Barclay, Stephen T.
Marx, Steven
Lohmann, Kristina
Bondin, Mark
Zhang, ZhenZhen
Marra, Fiona
Belperio, Pamela S.
Wedemeyer, Heiner
Flamm, Steven
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-020-01449-0
- URN
-
urn:nbn:de:101:1-2020112701575439543947
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lampertico, Pietro
- Mauss, Stefan
- Persico, Marcello
- Barclay, Stephen T.
- Marx, Steven
- Lohmann, Kristina
- Bondin, Mark
- Zhang, ZhenZhen
- Marra, Fiona
- Belperio, Pamela S.
- Wedemeyer, Heiner
- Flamm, Steven
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Response of treatment-naive brain metastases to stereotactic radiosurgery
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
ICG-r15 predicts esophageal varices in compensated liver cirrhosis: a noninvasive approach
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Response of treatment-naive brain metastases to stereotactic radiosurgery
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
ICG-r15 predicts esophageal varices in compensated liver cirrhosis: a noninvasive approach
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Efficacy and safety of TMC278 in treatment-naïve, HIV-infected patients: week 96 data from TMC278-C204
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Response of treatment-naive brain metastases to stereotactic radiosurgery
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression